Perhimpunan Dokter Paru Indonesia - Development of an antibody therapy for the treatment of pneumonia
RSS Feed klikPDPI.com twitter PDPI Facebook Page - Kedokteran Paru & Respirologi Forum Respirologi (Umum) Foto Operasional web PDPI Foto Operasional web PDPI
Members
Untitled Document
News
1 2 3 4 5
Mitra Kerja
Video

Tutorial Aplikasi ISR

Bahaya Rokok Elektrik
 
Development of an antibody therapy for the treatment of pneumonia




Jenny Herbert1,2 and Timothy Mitchell1
1Infection, Immunity and Inflammation, University of Birmingham, Birmingham, United Kingdom,2Institute of Child Health, University College London, London, United Kingdom

Streptococcus pneumoniae is the leading cause of bacterial pneumonia, one of the biggest killers of children under the age of 5 worldwide. The current first line of treatment for pneumococcal pneumonia and bacteraemia is beta-lactam antibiotics, which is contributing to increased antibiotic resistance. In the pre-antibiotic era serum therapy was successfully used for the treatment of pneumococcal infections. This used antibody rich serum raised in horses to treat patients with pneumococcal pneumonia and bacteraemia, clearing the infection. We propose to use the same approach to develop an antibiotic independent treatment using antibodies that target the pneumococcus.

Methods: MF1 outbred mice were infected intranasally with S.pneumoniae. Antibodies against the capsule and a panel of pneumococcal proteins were administered intraperitoneally 3-24h post infection. Disease progression was monitored using a clinical scoring system. Survival and bacterial load in the organs and blood were also monitored.

Results: Early administration of anti-capsular antibodies prevented disease progression at 3, 6 and 12 hours post infection. At 24 hours once bacteria are present within all organs clearance by anti-capsular antibodies was not observed. Antibodies against the chosen protein targets were not effective at clearing infection.

Conclusion: Early administration of anti-capsular antibodies prevented disease progression. We believe this approach could eventually be used in a clinical setting on patients showing symptoms of pneumonia and sepsis. For protein antibodies more work needs to be done to evaluate a larger panel of antibodies and what the protective epitopes are.

http://erj.ersjournals.com/content/48/suppl_60/PA2623



PP-PDPI. 04/03/17.



Halaman Siap Cetak  Halaman Siap Cetak

Kirimkan Pada Rekan  Kirimkan Pada Rekan
 

Free Web Counters

©2003 Perhimpunan Dokter Paru Indonesia
Privacy Policy  webmaster@klikpdpi.com


 
Intranet PDPI